HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
AMBIEN safely and effectively. See full prescribing information for
AMBIEN
AMBIEN
®
(zolpidem tartrate) tablets, for oral use, C-IV
Initial US Approval: 1992
----------------------------RECENT MAJOR CHANGES------------------------
Dosage and Administration, Dosage in Adults (2.1) 08/2016
Dosage and Administration, Special Populations (2.2) 12/2016
Warnings and Precautions, CNS Depressant Effects and Next-
Day Impairment (5.1) 08/2016
Warnings and Precautions, Precipitation of Hepatic
Encephalopathy (5.7) 12/2016
----------------------------INDICATIONS AND USAGE---------------------------
AMBIEN, a gamma-aminobutyric acid (GABA) A agonist, is indicated for the
short-term treatment of insomnia characterized by difficulties with sleep
initiation. (1)
----------------------DOSAGE AND ADMINISTRATION-----------------------
• Use the lowest dose effective for the patient and must not exceed a total of
10 mg daily (2.1)
• Recommended initial dose is a single dose of 5 mg for women and a single
dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8
hours remaining before the planned time of awakening (2.1)
• Geriatric patients and patients with mild to moderate hepatic impairment:
Recommended dose is 5 mg for men and women (2.2)
• Lower doses of CNS depressants may be necessary when taken
concomitantly with AMBIEN (2.3)
• The effect of AMBIEN may be slowed if taken with or immediately after a
meal (2.4)
---------------------DOSAGE FORMS AND STRENGTHS----------------------
5 mg and 10 mg tablets. Tablets not scored. (3)
-------------------------------CONTRAINDICATIONS------------------------------
Known hypersensitivity to zolpidem (4)
----------------------WARNINGS AND PRECAUTIONS-------------------------
• CNS depressant effects: Impairs alertness and motor coordination. Instruct
patients on correct use. (5.1)
• Need to evaluate for co-morbid diagnosis: Reevaluate if insomnia persists
after 7 to 10 days of use. (5.2)
• Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis
have been reported. Do not rechallenge if such reactions occur. (5.3)
• “Sleep-driving” and other complex behaviors while not fully awake. Risk
increases with dose and use with other CNS depressants and alcohol.
Immediately evaluate any new onset behavioral changes. (5.4)
• Depression: Worsening of depression or suicidal thinking may occur.
Prescribe the least amount of tablets feasible to avoid intentional overdose.
(5.5)
• Respiratory Depression: Consider this risk before prescribing in patients
with compromised respiratory function (5.6)
• Hepatic Impairment: Avoid AMBIEN use in patients with severe hepatic
impairment. (5.7)
• Withdrawal effects: Symptoms may occur with rapid dose reduction or
discontinuation (5.8, 9.3)
• Severe Injuries: Drowsiness may lead to fall including severe injuries (5.9)
-----------------------------ADVERSE REACTIONS--------------------------------
Most commonly observed adverse reactions were:
Short-term (< 10 nights): Drowsiness, dizziness, and diarrhea
Long-term (28 - 35 nights): Dizziness and drugged feelings (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis
U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088, or
http://www.fda.gov/medwatch
------------------------------DRUG INTERACTIONS-------------------------------
• CNS depressants, including alcohol: Possible adverse additive CNS-
depressant effects (5.1, 7.1)
• Imipramine: Decreased alertness observed (7.1)
• Chlorpromazine: Impaired alertness and psychomotor performance
observed (7.1)
• CYP3A4 inducers (e.g. rifampin): Combination use may decrease effect
(7.2)
• CYP3A4 inhibitors (e.g. ketoconazole): Combination use may increase
effect (7.2)
------------------------USE IN SPECIFIC POPULATIONS-----------------------
• Pregnancy: Based on animal data, may cause fetal harm (8.1)
• Pediatric use: Safety and effectiveness not established. Hallucinations
(incidence rate 7%) and other psychiatric and/or nervous system adverse
reactions were observed frequently in a study of pediatric patients with
Attention-Deficit/Hyperactivity Disorder (5.4, 8.4)
See 17 for PATIENT COUNSELING INFORMATION and Medication
Guide.
Revised: 12/2016
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Dosage in Adults
2.2 Special Populations
2.3 Use with CNS Depressants
2.4 Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 CNS Depressant Effects and Next-Day Impairment
5.2 Need to Evaluate for Co-morbid Diagnoses
5.3 Severe Anaphylactic and Anaphylactoid Reactions
5.4 Abnormal Thinking and Behavioral Changes
5.5 Use in Patients with Depression
5.6 Respiratory Depression
5.7 Precipitation of Hepatic Encephalopathy
5.8 Withdrawal Effects
5.9 Severe Injuries
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 CNS-active Drugs
7.2 Drugs that Affect Drug Metabolism via Cytochrome P450
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Labor and Delivery
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Gender Differences in Pharmacokinetics
8.7 Hepatic Impairment
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
9.2 Abuse
9.3 Dependence
10 OVERDOSAGE
10.1
Signs and Symptoms
10.2 Recommended Treatment
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Transient Insomnia
14.2 Chronic Insomnia
14.3 Studies Pertinent to Safety Concerns for Sedatives/Hypnotic
Drugs
Reference ID: 4022123